argenx SE
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands (Kingdom of the)
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
argenx SE is a biotechnology company that focuses on developing immunology solutions to help patients with autoimmune diseases. The company strives to co-create innovative therapies that will make a life-changing difference for patients. Arganx SE is committed to leveraging the power of the immune system to develop therapeutic solutions for some of the toughest autoimmune diseases out there. The company has a team of highly committed professionals with expertise in medical writing, clinical development, regulatory affairs, and other related fields who work closely to drive innovation and create solutions to help patients reach their full potential.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-11 08:15 |
Inside Information Statement
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase…
|
English | 154.7 KB | |
| 2025-03-20 07:09 |
Annual Report (ESEF)
argenx SE, Jaarlijkse financiële verslaggeving
|
English | 33.5 MB | |
| 2025-03-07 07:41 |
Company Presentation
argenx Highlights FcRn Leadership with Long-term Data and Transformational Pati…
|
English | 180.7 KB | |
| 2025-01-06 07:42 |
Regulatory News Service
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
|
English | 21.5 KB | |
| 2024-12-27 08:43 |
Regulatory News Service
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc)…
|
English | 63.3 KB | |
| 2024-11-26 07:38 |
Regulatory News Service
argenx to Present at Upcoming Investor Conferences
|
English | 26.2 KB | |
| 2024-11-11 13:45 |
Regulatory News Service
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammator…
|
English | 59.1 KB | |
| 2024-11-05 07:35 |
Regulatory News Service
argenx to Participate at Upcoming Investor Conferences
|
English | 25.1 KB | |
| 2024-10-31 07:40 |
Earnings Release
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
|
English | 154.5 KB | |
| 2024-10-24 07:40 |
Earnings Release
argenx to Report Third Quarter 2024 Financial Results and Business Update on Oc…
|
English | 22.7 KB | |
| 2024-09-19 09:48 |
Regulatory News Service
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Da…
|
English | 108.5 KB | |
| 2024-08-28 08:38 |
Regulatory News Service
argenx to Present at Upcoming Investor Conferences
|
English | 25.6 KB | |
| 2024-07-25 07:37 |
Earnings Release
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Bus…
|
English | 143.7 KB | |
| 2024-07-18 07:38 |
Earnings Release
argenx to Report Half Year 2024 Financial Results and Second Quarter Business U…
|
English | 20.4 KB | |
| 2024-07-16 07:31 |
Regulatory News Service
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneo…
|
English | 98.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |